46 results about "Urological Diseases" patented technology

Embodiments of the present invention provide a device and a method for treating at least one of hypertension, pulmonary arteries, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, nonalcoholic fatty liver disease, urological disease, cancers, tumors, pain, asthma or chronic obstructive pulmonary disease by delivering an effective amount of a formulation to a tissue. In embodiments of the present invention, the formulation may include at least one of a gas, a vapor, a liquid, a solution, an emulsion, or a suspensions of one or more ingredients. In embodiments of the present invention, amounts of the formulation and or energy are effective to injure or damage tissue, nerves, and nerve endings in order to relieve disease symptoms.

The transdermal permeable property of solifenacin or a salt thereof as a biologically active substance, is remarkably improved using a fatty acid ester, a terpene or the like as a selected transdermal permeable promoter. The difference in effect exceeded expectations by producing an enhancement in permeability that represents an increase of several hundredfold at most, and several tenfold for practical application, enabling the provision of extremely useful means for preventive and therapeutic agents for urologic diseases or respiratory diseases that use solifenacin.

The present invention relates to phenyl or heteroaryl amino alkane derivatives of formula (I)

in which the groups Q¹-Q⁴, Ar, and R¹-R⁷ are as defined in the specification and claims. These materials are useful as active ingredients of pharmaceutical preparations. The phenyl or heteroaryl amino alkanes of the present invention have IP receptor antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with IP receptor antagonistic activity. Such diseases include urological diseases or disorders as follows: bladder outlet obstruction, overactive bladder, urinary incontinence, detrusor hyper-reflexia, detrusor instability, reduced bladder capacity, frequency of micturition, urge incontinence, stress incontinence, bladder hyperreactivity, benighn prostatic hypertrophy (BPH), prostatitis, urinary frequency, nocturia, urinary urgency, pelvic hypersensitivity, urethritis, pelvic pain syndrome, prostatodynia, cystitis, or idiophatic bladder hypersensitivity. The compounds of the present invention are also useful for treatment of pain including, but not limited to inflammatory pain, neuropathic pain, acute pain, chronic pain, dental pain, premenstrual pain, visceral pain, headaches, and the like; hypotension; hemophilia and hemorrhage; and inflammation, since these diseases also are alleviated by treatment with an IP receptor antagonist. The application claims the compounds, pharmaceutical compositions containing them, and methods of treatment using them.

The invention provides LTBP2, which is associated with cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of LTBP2 as well as pharmaceutical compositions comprising such compounds. The invention also provides LTBP2 as a biomarker for diseases such as cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases.

The present invention relates to methods for the diagnosis and treatment of a urological disorder or urological disorders. Specifically, the present invention identifies the differential expression of Carboxypeptidase Z, identified as “8263” gene in tissues relating to urological disorder, relative to their expression in normal, or non-urological disorder disease states, and/or in response to manipulations relevant to a urological disorder. The present invention describes methods for the diagnostic evaluation and prognosis of various urological diseases, and for the identification of subjects exhibiting a predisposition to such conditions. The invention also provides methods for identifying a compound capable of modulating a urological disorder or urological disorders. The present invention also provides methods for the identification and therapeutic use of compounds as treatments of urological disorders.

Embodiments of the present invention provide a device and a method for treating at least one of hypertension, pulmonary arteries, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, nonalcoholic fatty liver disease, urological disease, cancers, tumors, pain, asthma or chronic obstructive pulmonary disease by delivering an effective amount of a formulation to a tissue. In embodiments of the present invention, the formulation may include at least one of a gas, a vapor, a liquid, a solution, an emulsion, or a suspensions of one or more ingredients. In embodiments of the present invention, amounts of the formulation and/or energy are effective to injure or damage tissue, nerves, and nerve endings in order to relieve disease symptoms.

An ultra sonic system is for treatment of urologic diseases. The system includes an ultrasonic generator providing the working field in the frequency range of 15 to 100 kHz and amplitude 2 to 180 mcm, an acoustic unit coupled to the generator and an ultrasonic instrument that connects rigidly with the acoustic unit. The ultrasonic instrument is a multi half-wave concentrator wave-guide, including a core with changeable cross-section and a working end. A length of the working end is to a length of the core as 3/100 to 3/40. The largest size of cross-section of the core in a place of connection with the working end is to the largest size of cross-section of the working end, as 1/20 to 6/1.

Embodiments of the present invention provide a device and a method for treating at least one of hypertension, pulmonary arteries, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pain, asthma or chronic obstructive pulmonary disease by delivering an effective amount of a formulation to a tissue. In embodiments of the present invention, the formulation may include at least one of a gas, a vapor, a liquid, a solution, an emulsion, or a suspensions of one or more ingredients. In embodiments of the present invention, amounts of the formulation and/or energy are effective to injure or damage tissue, nerves, and nerve endings in order to relieve disease symptoms.

This invention relates to bicyclic amide, carbamate or urea derivatives and salts thereof which are useful as active ingredients of pharmaceutical preparations. The bicyclic amide, carbamate or urea derivative of the present invention has vanilloid receptor (VR1) antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urological diseases or disorders, such as detrusor overactivity (overactive bladder), urinary incontinence, neurogenic detrusor oeractivity (detrusor hyperflexia), idiopathic detrusor overactivity (detrusor instability), benign prostatic hyperplasia, and lower urinary tract symptoms; chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, and inflammatory disorders such as asthma and chronic obstructive pulmonary (or airways) disease (COPD).

The invention discloses a novel urethra dosing device for urinary surgery, and belongs to the field of urological disease treatment instruments. The novel urethra dosing device comprises a syringe, and a cleaning liquid pushing and injecting cavity, a cleaning dirt suction cavity and a dosing cavity which are separated from one another are arranged in the syringe; the cleaning liquid pushing and injecting cavity and the cleaning dirt suction cavity surround the dosing cavity, and a dosing chamber communicated with the dosing cavity is formed among the cleaning liquid pushing and injecting cavity, the cleaning dirt suction cavity and the syringe; the outer surface of the syringe is in wavy shape, wherein protruding parts and concave parts on the outer surface of the syringe are connected alternately, the front end face of each protruding part is provided with a cleaning liquid spraying pipe, the outer end of each protruding part is provided with a medicine spraying opening, and each concave part is provided with a suction pipe; a first piston, a second piston and a third piston are arranged in the cleaning liquid pushing and injecting cavity, the cleaning dirt suction cavity and thedosing cavity respectively. According to the dosing device, a cleaning mechanism and a power source mechanism of a sewage discharge mechanism are integrated, the dosing device is convenient to control, operation is simplified, secondary infection caused by pollutants to the urethra can be prevented, and a clean application environment is provided for liquid medicine; complete output of the liquidmedicine is achieved, dosing is uniform, and drug effects of the liquid medicine can be given play of.

The invention provides a human PRSC1 which is associated with the cardiovascular diseases, cancer, endocrinological diseases, metabolic diseases, inflammation, gastroenterological diseases, hematological diseases, respiratory diseases, neurological diseases and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, cancer, endocrinological diseases, metabolic diseases, inflammation, gastroenterological diseases, hematological diseases, respiratory diseases, neurological diseases and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of PRSC1 as well as pharmaceutical compositions comprising such compounds.

The invention discloses pharmic tadalafil composition granules for treating urological diseases, and belongs to the technical field of medicament. A composition is prepared from tadalafil, saccharose, glucose, glycine, polyethylene glycol and purified water. The tadalafil is a novel crystal-type compound, an X-ray powder diffraction pattern measured through a Cu-K alpha-ray is shown in graph 1, and the tadalafil is different from that reported in the prior art; according to experiments, it is found that the compound with the novel crystal-type structure has significantly improved water solubility and is low in impurity content and good in stability; the granules prepared from the novel crystal-type tadalafil compound is good in stability, low in impurity content and high in bioavailability, and the safety of clinical applications is improved.

The invention provides a preparation method of a recovery composition for urological diseases of the prostate, and relates to the field of grease synthesis. 8-10 carbon fatty acid triglyceride, 16-24carbon fatty acid triglyceride, conjugated linoleic acid glyceride and phytosterol are taken as raw materials and are subjected to a transesterification reaction, and after cooling, decoloring, deodorization, distillation and refined filtration, a vitamin E and ascorbyl palmitate are added to obtain 6-24 carbon long-medium-chain triglyceride; after emulsification, homogenization, embedding and spray drying, the 6-24 carbon long-medium-chain triglyceride is mixed with a functional mixture to prepare the lipid composition of a long-medium-chain structure. The method is simple, convenient and lowin cost, and the prepared composition can be used for recovery of the urological diseases of the prostate and the like.

The invention discloses a pharmaceutical tadalafil composition tablet for treating urological diseases and belongs to the technical field of medicine. A composition is made from tadalafil, lactose, pregelatinized starch, polyvinyl butyral, carboxyvinyl polymer and magnesium stearate. The tadalafil is a novel-crystal form compound, an X-ray powder diffraction pattern obtained by measurement using Cu-Ka ray is shown in 1, the tadalafil is one different from the prior art, testing shows that the novel-crystal form compound has significantly improved water solubility, low impurity content and good stability, a tablet prepared with the tadalafil novel-crystal form compound has higher dissolution than the prior art, good stability and low impurity content and is safer to clinically apply.

The present invention relates to carboxamides which are useful as an active ingredient of pharmaceutical preparations. The carboxamides of the present invention have IP receptor antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with IP receptor antagonistic activity. Such diseases include urological diseases or disorder as follows: bladder outlet obstruction, overactive bladder, urinary incontinence, detrusor hyper-reflexia, detrusor instability, reduced bladder capacity, frequency of micturition, urge incontinence, stress incontinence, bladder hyperreactivity, benighn prostatic hypertrophy (BPH), prostatitis, urinary frequency, nocturia, urinary urgency, pelvic hypersensitivity, urethritis, pelvic pain syndrome, prostatodynia, cystitis, or idiophatic bladder hypersensitivity. The compounds of the present invention are also useful for treatment of pain including, but not limited to inflammatory pain, neuropathic pain, acute pain, chronic pain, dental pain, premenstrual pain, visceral pain, headaches, and the like; hypotension; hemophilia and hemorrhage; and inflammation, since the diseases are alleviated by treatment with an IP receptor antagonist.

To provide a compound useful as an MC4 receptor agonist. The present inventors have made studies on MC4 receptor agonists. As a result, it is confirmed that a piperazine derivative has an MC4 receptoragonist activity, which leads to the accomplishment of the present invention. The piperazine derivative according to the present invention has an MC4 receptor agonist activity, and therefore can be used as a prophylactic or therapeutic agent for disturbance of urination in bladder and urinary tract diseases, particularly underactive bladder, hypotonic bladder, acontractile bladder, detrusor underactivity, neurogenic bladder, urethral relaxation failure, detrusor-sphincter dyssynergia and prostatic hyperplasia.